Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
In Mexico, obesity is a major public health problem. In recent years he has presented a
considerable increase in the population. As a result, it has triggered a proportional
increase in the incidence of cardiovascular disease and the development of Metabolic Syndrome
(METS). Abdominal obesity is one of the main components of METS which is generally associated
with insulin resistance / hyperinsulinemia. This is influenced both by the subcutaneous
adipose tissue as visceral adipose tissue. There is evidence that the visceral fat has an
important bearing on many factors of METS, like: glucose intolerance, hypertension,
dyslipidemia, and insulin resistance.
For management it requires a multidisciplinary approach, including changes in lifestyle,
psychological and nutritional intervention as well as pharmacological and non-pharmacological
support.
Among non-pharmacological therapies, there is recently the use of Conjugated Linoleic Acid
(ACL) and leucine where in its assigned properties include weight reduction, anti-atherogenic
, hypocholesterolemic and immunostimulant effect and anticarcinogenic properties. Regarding
weight reduction dominates the mechanism of action anti-lipolytic effect. But, studies are
needed to link this consumption with the increase or decrease on visceral fat in individuals
with METS.
Phase:
Phase 2
Details
Lead Sponsor:
Centro Universitario de Ciencias de la Salud, Mexico